. The mammalian N-end rule pathway. N-terminal residues are indicated by single-letter abbreviations for amino acids. A yellow oval denotes the rest of a protein substrate. E3 ubiquitin (Ub) ligases of the N-end rule pathway are called N-recognins.
(A) The Arg/N-end rule pathway. "Primary", "secondary" and "tertiary" denote mechanistically distinct subsets of destabilizing N-terminal (Nt) residues. C* denotes oxidized N-terminal Cys, either Cys-sulfinate or Cys-sulfonate, produced in vivo by reactions that require nitric oxide (NO) and oxygen. Oxidized N-terminal Cys is N α -terminally arginylated (Nt-arginylated) by ATE1-encoded isoforms of arginyl-tRNA-protein transferase (R-transferase), which also arginylates N-terminal Asp (D) and Glu (E) . N-terminal Asn (N) and Gln (Q) are deamidated by the NTAN1-encoded Nt Figure S2 . Evolutionary conservation of the destabilizing nature of P1' residues in the cleavage sites that yield the natural fragments of TDP43, α-Synuclein, and Tau. (A P1' residue becomes N-terminal upon protein cleavage.) (A) Domain organization of TDP43. Arrowheads indicate the cleavage sites 1, 2 and 3 in full-length TDP43 that yield the natural C-terminal fragments isolated from protein aggregates in human FTLD-TDP brains (see Figure 1 and the main text) (Igaz et al., 2009; Nonaka et al., 2009; Pesiridis et al., 2011; Wang et al., 2012) . The identity of protease(s) that generates these TDP43 fragments is unknown. The indicated residue numbers, including those of P1' residues (these residues are in color and in a lager font size), are of the full-length human TDP43. Note the complete conservation of the P1' Asp (D) residues at the cleavage sites 2 and 3 (positions 219 and 247). Note also the "drift-with-constraint" evolutionary pattern of the P1' residues in the cleavage site 1 (see the main text). Specifically, a P1's residue is Arg (R) in most species but Gln (Q), another destabilizing residue, in the mouse, rat, and chicken.
(B) Domain organization of human α-synuclein. Arrowhead indicates the metalloprotease cleavage site (Choi et al., 2011) . (Metalloproteases are usually extracellular but can occur in the cytosol as well (Cauwe and Opdenakker, 2010) .) For notations, see A. Analogously to the evolutionary pattern observed with P1' residues in the cleavage site 1 of TDP43 in A, most P1 residues in the cleavage site of α-synuclein are Gln (Q), at position 79 of the human α-synuclein. However, some mammals (such as guinea pigs), some frogs (such as Xenopus laevis), and some fishes (such as pikes) contain His at the P1' position of their α-synucleins ( Figure S2B ). Both N-terminal Gln and His are destabilizing residues ( Figure S1A ). Yet another informative aspect of evolution of the P1' residue of α-synuclein is that all changes of the predominant Gln at the P1' position (equivalent to position 79 in human α-synuclein) in separate vertebrate lineages (mammals, frogs, fishes) were invariably to His, rather than to another residue. A plausible explanation stems from the fact that the CAA/CAG codons for Gln differ from the CAT/CAC codons for His by one nucleotide. A similar interpretation is also relevant to the evolutionary change of a P1's residue at position 208 in human TDP43 (panel A): the alteration from Arg to Gln at the P1' position of full-length TDP43 in vertebrates involved a single-base transition between the CGG Arg codon and the CAG Gln codon.
(C) Domain organization of the human Tau-2N isoform. Two arrowheads indicate the calpain cleavage sites. In the first of them, the P1' residue of human Tau is Glu (E), at position 3. The third cleavage site is specific for caspases, in particular caspase-6, with the P1' residue being His (H), at position 14 (Spires-Jones et al., 2011; Zilka et al., 2012) . In yet another example of the drift-with-constraint evolutionary pattern of P1' residues seen above with TDP43 and α-synuclein (panels A and B), the P1' residue at position 3 of the calpain cleavage site of Tau-2N is Glu in humans, horses, rats, chickens and other vertebrates, but is Asp in mice. Both His, Glu and Asp are destabilizing residues ( Figure S1A ). Caspases have been shown to cleave human Tau-2N between Asp13 and His14, and also 19 residues upstream of its C-terminus, at Asp421-Ser422, with the former cleavage mediated by at least caspase-6 ( (Horowitz et al., 2004) and refs. therein). The Asp13-His14 cleavage produces the N-terminally truncated Tau bearing N-terminal His, a destabilizing residue. The resulting His14-Tau is yet another (predicted) physiological substrate of the Arg/N-end rule pathway. All but one among the examined mammalian Tau sequences has His at the P1' position (this residue becomes N-terminal after caspase cleavage). The only exception, rat Tau, has Gln (Q) at this position, but both His and Gln are destabilizing residues, a recurrent example of the drift-with-constraint pattern of P1' residues described above for other neurodegeneration-associated fragments.
The evolutionary retention of a destabilizing nature of a P1' residue in a precursor of a caspase-generated fragment of any protein (not only of Tau) is noteworthy for an additional and independent reason as well. More than 90% of caspase cleavage sites in cellular proteins contain, at their P1' positions, small residues such as Gly, Ser , Thr and Ala (Crawford and Wells, 2011; Pop and Salvesen, 2009 ). These residues are not recognized by the Arg/N-end rule pathway ( Figure S1A ). Thus, remarkably, the destabilizing P1' residues His or Gln in the precursors of caspase-generated X14-Tau fragments in different mammals (let alone the evolutionary conservation of these residues) would not be expected on a priori grounds, given the major preponderance of smaller P1' residues in caspase substrates at large. Together with our previous findings (Piatkov et al., 2012a; Varshavsky, 2012) , these results strongly suggest adaptive (fitness-increasing) origins of the observed destabilizing P1' residues in the precursors of the TDP43, α-synuclein, and Tau fragments examined in the present work. Figure 
SUPPLEMENTAL EXPERIMENTAL PROCEDURES

Miscellaneous Reagents
Cycloheximide was from Sigma (St. Louis, MO). Human cDNAs encoding proteins examined in the present work were from OpenBiosystems (Huntsville, AL). MG132 (BML-PI102-0005) and clasto-Lactacystin β-Lactone (BML-PI108-0100) were from EnzoLife Sciences (Farmingdale, NY). Epoxomicin (E3652), Thiorphan (T6031), Racecadotil (SML0043), Phosphoramidon (R7385) and Verapamil (V4629) were from Sigma. The following antibodies were used: anti-FLAG M2 (Sigma, F1804), anti-c-Myc (Sigma, C3956), anti-Beta-Amyloid (4G8) (Covance, SIG-39220), anti-Amyloid Precursor Protein (Calbiochem, 171610); and affinity-purified polyclonal antibody to mouse Ate1 (Hu et al., 2005) . The following reagents were used for immunoprecipitation: anti-flag M2 Magnetic Beads (Sigma, M8823) and EZview Red anti-c-Myc affinity gel (Sigma, E6654). Detection was carried out using HRP-conjugated goat anti-Rabbit (BioRad, 170-6515) or anti-mouse (BioRad, 170-6516) antibodies and either ECL Prime Western Blotting Detection System (GE Healthcare, UK) or SuperSignal West Femto reagents (Thermo Scientific, Rockford, IL), according to manufacturers' protocols. 5xFAD mice were obtained from The Jackson Laboratories (JAX stock number 006554). Postmortem human brain tissue was obtained from the Harvard Brain Tissue Resource Center.
Plasmids, cDNAs, and Primers
DH5α E. coli (Invitrogen) was used for cloning and maintaining plasmids. Phusion High-Fidelity DNA polymerase (New England Biolabs) was used for polymerase chain reaction (PCR). Sequences of all constructed plasmids were verified by DNA sequencing.
Asp-Aβ42
13myc
. cDNA encoding human Aβ42 sequence ( Figure 4A ) was amplified by PCR using a set of overlapping forward primers (CB302F, CB268F, CB269F, CB270F, and CB271F) and reverse primers (CB272R, CB273R, CB274R, and CB304R) (Table S2 ) whose assembled sequence contained DNA encoding human Aβ42. The resulting DNA fragment was inserted into pFA6a-13Myc-kanMX6 (Table S1 ) using SacII/SmaI sites to produce pCB253. The Aβ42 13myc -coding sequence was removed from pCB253 using SacII/EcoRI and inserted into SacII/EcoRI-cut pCH280 (Hwang et al., 2009 ) to produce pCB255, a low copy plasmid which was used to express f DHFR-Ub R48 -Asp-Aβ42 13myc from the P MET25 promoter in S. cerevisiae.
f DHFR-Ub R48 -X-Aβ42 13myc fusions (X=Met, Val, Arg-Asp) were constructed by amplifying the human Aβ42-coding DNA fragment with the following sets of primers: CB313F and CB304R (Met-Aβ42 13myc ); CB314F and CB304R (Val-Aβ42 13myc ); CB316F and CB304R (Arg-Asp-Aβ42 13myc ). The resulting fragments were cut with SacII and SmaI, and cloned into SacII/SmaI-cut pCB255 to produce the plasmids pCB255, pCB282, pCB284, and pCB285 (Table S1 ). For 35 S-pulse-chase URT-based assays in rabbit reticulocyte extract, the DNA fragment encoding f DHFR-Ub-Asp-Aβ 13myc was removed from pCB255 by HindIII digestion and inserted into HindIII-cut pcDNA3.0 (Invitrogen) to produce pCB268 (Table S1 ).
TDP43. The human Tdp43 cDNA was obtained from OpenBiosystems (ID: LIFESEQ2505218). DNA fragments encoding X208-TDP43 C-terminal fragments (X=Arg, Met, Gln, and Glu) were constructed by amplification, using the following sets of primers: CB320F and CB327R (Arg208-TDP43); CB321F and CB327R (Met208-TDP43); CB322F and CB327R (Gln208-TDP43); and CB323F and CB327R (Glu208-TDP43) (Table S2 ). C-terminal flag tags were added by sequential PCR extension using the above forward primers with, at first, CB275R, and then CB280R. The resulting PCR products, which encoded X208-TDP43 f , were cut with SacII/XbaI and cloned into SacII/XbaI-cut pCB268, producing the plasmids pCB322, pCB323, pCB234, and pCB325 (Table S1 ). DNA encoding X219-TDP43 f C-terminal fragments (X=Asp, Met, Val, and Arg-Asp) were amplified from pCB323 using the following sets of primers: CB330F and CB329R (Asp219-TDP43 f ); CB331F and CB329R (Met219-TDP43 , were cut with SacII/XbaI and cloned into SacII/XbaI-cut pCB268, producing the plasmids pCB326-pCB333 (Table S1 ).
For mammalian expression using the weaker (relative to the P CMV promoter) P SV40 promoter, DNA fragments encoding the f DHFR-Ub-X-TDP43 f fusions in pcDNA3.0-based plasmids (containing the P CMV promoter) were used to replace the luciferase reporter in pGL3-Control plasmid (Promega) after digestion with HindIII/XbaI.
To construct the plasmid pCB400, used in in vivo aggregation assays ( Figure 2C -E), DNA encoding mCherry was amplified from pKP551 (Table S1 ) using primers CB383F and CB384R, and the resulting PCR product was used to replace the f DHFR moiety in pCB338 after digestion with HindIII/AgeI . α-Synuclein. The human α-synuclein cDNA was obtained from OpenBiosystems (ID: 5287266). DNA encoding X79-αSyn f (X= Gln and Val) were constructed by amplification with the following sets of primers: CB364F and CB367R (Gln79-αSyn); and CB365F and CB367R (Val79-αSyn). The resulting DNA fragments were cut with SacII/XbaI, and cloned into SacII/XbaI-cut pCB268, generating the plasmids pCB347 and pCB348 (Table S1) .
Tau. The human Tau-1N cDNA (lacking exon 3) was obtained from OpenBiosystems (ID: LIFESEQ6770882). DNA encoding X 3 -Tau-1N 95f (X= Glu and Val) were constructed by amplification with the following sets of primers: CB373F and CB377R (Glu3-TauN1) and CB375F and CB377R (Val3-TauN1). CB377 encoded the C-terminal sequence PGSDYKDDDDK, containing the linker and the flag epitope. Human Tau-2N cDNA (containing exon 3) was obtained by a three-step PCR strategy whereby the N-terminal portion of the Tau 3-124 -coding fragment was amplified using the above forward primers and CB379R (whose 5'-proximal region is the reverse complement of the 5'-region of CB380F). The Cterminal portion of the Tau 3-124 -coding fragment was amplified using CB380F (whose 5'-proximal region is the reverse complement of the 5'-region of CB379R) and CB377R. The entire Tau-2N 3-124 -coding fragment was amplified using the overlapping N-and C-terminal fragments as templates in a final PCR step that employed CB373F and CB377R (Glu3-Tau-2N 124 ) as well as CB375F and CB377R (Val3-Tau-2N 124 ). The resulting DNA fragments were cut with SacII/XbaI and cloned into SacII/XbaI-cut pCB268, producing the plasmids pCB383, pCB385, pCB386, and pCB388 (Table S1 ).
In Vitro Transcription-Translation-Degradation Assay
The TNT T7 Coupled Transcription/Translation System, a version of the Promega's rabbit reticulocyte extract preparation in which the main components of the system were supplied separately, was used to carry out transcription-translation-degradation assays. Reaction samples were prepared according to the manufacturer's instructions. Nascent proteins in reticulocyte extract were pulse-labeled with [
35 S]L-methionine (0.55 mCi/ml, 1,000 Ci/mmol, MP Biomedicals) for 10 min at 30°C, in the total volume of 30 µl. The labeling was quenched by the addition of cycloheximide and unlabeled methionine, to the final concentrations of 0.1 mg/ml and 5 mM, respectively. Samples were withdrawn at indicated timepoints of a chase and the reactions were terminated by the addition of 0.1 ml of TSD buffer (1% SDS, 5 mM dithiothreitol (DTT), 50 mM Tris-HCl, pH 7.4) and snap-freezing in liquid nitrogen. Samples were then heated at 95°C for 10 min, diluted with 10 volumes of TNN buffer (0.5 % NP-40, 0.25 M NaCl, 5 mM EDTA, 50 mM Tris-HCl, pH 7.4), containing the "complete protease-inhibitor mixture" (Roche), clarified by centrifugation at 20,000g for 5 min and immunoprecipitated using 5 μl of beads with an immobilized antibody, either anti-flag M2 Magnetic Beads or EZview Red anti-c-Myc affinity gel. The immunoprecipitates were incubated with rocking at 4°C for 3 hr, followed by 3 washes in TNN buffer, one wash in 10 mM Tris-HCl (pH 8.5), and resuspension in 20 μl of SDS-sample buffer. Samples were then heated at 95°C for 10 min and fractionated by SDS-4-15% PAGE, followed by autoradiography, using Storm PhosphorImager (Molecular Dynamics, Sunnyvale, CA), and quantification, using ImageQuant (GE Healthcare).
Cell Culture
Mouse NIH-3T3 and human HEK-293T cells were obtained from American Type Culture Collection (ATCC, Manassas, VA). Ate1 -/-mouse embryonic fibroblasts (EFs) were described previously (Kwon et al., 2002) . Cells were grown at 37°C in 5% CO 2 in DMEM medium supplemented with 10% fetal bovine serum (FBS) (Gemini Bio-Products, West Sacramento, CA) and penicillin/streptomycin (100 units/ml) (Hyclone). Cells were transfected using Lipofectamine-2000 (Invitrogen) according to the manufacturer's protocol.
In Vivo Degradation Assay
Human embryonic kidney-293T cells (~75% confluent) were transfected with 1 µg plasmid per 35-mm well using Lipofectamine-2000 according to the manufacturer's protocol. Forty hours post-transfection cells were pulse-labeled for 15 min with [
35 S]L-methionine (0.1 mCi/ml, MP Biomedicals) in DMEM lacking Met and Cys. Labeling was quenched by the addition of cycloheximide (0.1 mg/ml) in complete DMEM (containing Met as well). Cells contained in an entire 35-mm well were lysed at the indicated timepoints of a chase by rapid scraping in 150 µl of TSD buffer (see above) and snap freezing in liquid nitrogen. Samples were then heated at 95°C for 10 min and diluted with 10 volumes of TNN buffer (see above) containing the "complete protease-inhibitor mixture" (Roche). Total 35 S (in the 10% CCl 3 COOH-insoluble fraction) in samples was then measured, and volumes were adjusted to equalize 35 S among different samples. Thus prepared samples were immunoprecipitated by the addition of 5 μl of anti-flag M2 magnetic beads and incubation with rocking at 4°C for 3 hr. Immunoprecipitated proteins were then washed 3 times in TNN buffer and once in 10 mM TrisHCl (pH 8.5), followed by resuspension in 20 μl of SDS-sample buffer, heating at 95°C for 10 min, SDS-4-15% PAGE, and autoradiography, with quantification as described above.
In Vivo Aggregation Assay
Poly-D-lysine (1 mg/ml)-coated coverslips were placed in 35-mm tissue culture dishes and 1.5 × 10 5 mouse embryonic fibroblasts (NIH-3T3 or Ate1 -/-) were seeded on top and grown until ~65% confluency. Cells were then transfected with 1 µg of pCB400 per plate, using Lipofectamine-2000. Twenty-four hrs after transfection, cells were fixed in 4% formaldehyde for 10 min at room temperature, and permeabilized in 0.5% Triton-X100 in PBS for 10 min at room temperature. Coverslips were then washed three times in PBS, and blocked in 10% goat serum for 30 min. Coverslips were incubated with anti-flag M2 antibody (at 1/1000 dilution in 5% goat serum/PBS containing 0.1% Tween-20) for 2 hrs at 37°C in a humid environment, followed by three 5 min washes in PBS containing 0.1% Tween-20 and incubation with fluorescein-conjugated anti-mouse secondary antibody (Pierce, #31567) (at 1/200 dilution in 5% goat serum/PBS containing 0.1% Tween-20) for 1 hr at 37°C in a humid environment. Coverslips were again washed 3 times in PBS containing 0.1% Tween-20, and thereafter were mounted using Vectashield H-1500 mounting medium containing DAPI (Vector Laboratories, Burlingame, CA). Thus processed coverslips were examined for fluorescence by mCherry, DAPI, and fluorescein-conjugated secondary anti-mouse antibody using Zeiss Axio Imager 2.
Steady-State and Pulse-Chase Assays of X-Aβ42 13myc in S. cerevisiae S. cerevisiae JD52 (MATa, and JD55 (ubr1Δ::HIS3 in JD52) were described previously (Ghislain et al., 1996) . S. cerevisiae CHY21 (ate1Δ::KanMX6 in JD52) and CHY22 (ubr1Δ::HIS3 in CHY21) were gifts from Dr. Cheol-Sang Hwang. S. cerevisiae media included YPD (1% yeast extract, 2% peptone, 2% glucose; only most relevant media components are cited); SD medium (0.17% yeast nitrogen base, 0.5% ammonium sulfate, 2% glucose); and synthetic complete (SC) medium (0.17% yeast nitrogen base, 0.5% ammonium sulfate, 2% glucose, plus a drop-out mixture of compounds required by auxotrophic strains). S. cerevisiae were transformed with the low copy pCB255, pCB282, pCB284, or pCB285 plasmids using standard techniques (Ausubel et al., 2010) . Expression of f DHFR-Ub-X-Aβ 13myc was induced by growth in SD(-Ura, -Met) for 6 hr at 30°C.
35
S-pulse-chase experiments with S. cerevisiae were performed essentially as described previously (Hwang et al., 2009) . Transformed yeast strains carrying low copy plasmids expressing test protein fusions were grown in 10 ml of SD(-Ura) medium at 30°C until A 600 of ~1.0. Cells were pelleted by centrifugation at 3,000g for 10 min and washed with 0.8 ml of fresh pre-warmed medium. Cell pellets were gently resuspended in 0.4 ml of the same medium but lacking Met/Cys, and incubated for 10 min at 30°C, followed by labeling for 5 min with [
35 S]L-methionine (0.55 mCi/ml, 1,000 Ci/mmol; MP Biomedicals). Cells were then pelleted by centrifugation and resuspended in 0.4 ml of YPD medium containing cycloheximide at 0.1 mg/ml (chase medium). Samples (0.1 ml) were taken at the indicated time points and added to 0.8 ml of the lysis buffer (1% TritonX-100, 0.15 M NaCl, 5 mM EDTA, 1 mM PMSF (phenylmethylsulfonyl fluoride, freshly dissolved), 50 mM HEPES, pH 7.5) containing "yeast protease inhibitor cocktail" (Roche), followed by rapid freezing in liquid nitrogen. Samples were thawed in thermomixer (Eppendorf) at 37°C for 2 min and thereafter treated by 4 runs in lysing matrix C (0.1 mM silica spheres) using FastPrep-24 (MP Biomedicals) (setting 6.5 m/s, 20 sec, with 2 min on ice between the runs). The resulting samples were centrifuged at 20,000g, and total 35 S (in the 10% CCl 3 COOH-insoluble fraction) in each sample was adjusted, by dilution with lysis buffer, to equalize 35 S among different samples. Thus prepared samples were immunoprecipitated using EZview Red anti-cMyc affinity gel. The unbound material was immunoprecipitated using anti-flag M2 magnetic beads. Immunoprecipitated proteins were fractionated by SDS-4-15% PAGE, electrophoretically transferred to PVDF membranes, detected by autoradiography, and quantified, using Storm PhosphorImager and ImageQuant.
Animal Care and Treatments
All animal care and procedures were carried out according to the NIH guidelines, and were approved by the Institutional Animal Care and Use Committee and the Office of Laboratory Animal Research (OLAR) at the California Institute of Technology. Mice were housed at ~22°C using a 12 hr light/12 hr dark cycle, with Laboratory Rodent Diet 5001 (PMI International, Richmond, IN) ad libitum. The proteasome inhibitors MG132 (25 µmol/kg) clastolactacystin β-lactone (1 µmol/kg), and epoxomicin (0.6 µmol/kg), as well as neprilysin inhibitors Thiorphan (12 mg/kg), Racecadotil (18 mg/kg), and Phosphoramidon (2.5 mg/kg), in addition to verapamil (45 mg/kg), an inhibitor of multidrug resistance transporters, were delivered intraperitoneally (two injections, 12 hrs apart). Twelve hours after the last injection, mouse brains were harvested and proteins were extracted as described below.
Tissue Extracts and Immunoblotting
Proteins were extracted from mouse and human brain samples using a three-step sequential procedure. First, brain tissue (225 mg per ml of buffer) was homogenized in TBS buffer (0.15 M NaCl, 50 mM Tris-HCl, pH7.4) containing "complete protease-inhibitor mixture" (Roche), using FastPrep-24 and Lysing Matrix D (MP Biomedicals), with 3 runs at 6.5 m/s for 30 sec each, and with 5-min incubations on ice between runs. TBS-insoluble material was pelleted by centrifugation at 100,000g for 40 min at 4°C in the TL-100.3 ultracentrifuge. The pellets were washed in TBS, and resuspended in TBS-X (TBS containing 1% Triton-X100) by rotation at 4°C for 30 min TBS-X-insoluble material was precipitated by centrifugation at 100,000g for 40 min at 4°C, washed in TBS, and resuspended in 70% HCOOH (formic acid (FA)), using multiple passages through a 26 gauge needle and overnight rotation 4°C. Material insoluble in 70% HCOOH was pelleted by centrifugation at 22,000g for 10 min at 4°C. Protein concentrations in TBS, TBS-X, and FA extracts were determined using Bio-Rad Protein Assay DyeReagent (BioRad, # 500-0006). HCOOH extracts were additionally dried in a Speed-Vac and washed with acetone. Equal total protein amounts from each sample were fractionated by SDS-16.5% PAGE (Criterion Tris-Tricine gels; BioRad, #345-0063), and proteins were transferred to 0.2 µm nitrocellulose membranes (BioRad, # 162-0112), which were then autoclaved in H 2 O to enhance epitope exposure to antibodies (Swerdlow et al., 1986) , followed by immunoblotting with the specified antibodies. Detection was carried out using ECL Prime Western blotting Detection System (GE Healthcare, UK) or SuperSignal West Fempto reagents (Thermo Scientific, Rockford, IL) according to manufacturer's protocol.
In Vitro Arginylation Assay
In vitro Ate1 arginyl-transferase (R-transferase) assays were carried out in 50-μl samples largely as described previously (Hu et al., 2006) . The samples contained either zero, 0.1, or 1.0 µg of purified recombinant Ate1-1, Ate1-2, Ate1-3, or Ate1-4 mouse transferase (Hu et al., 2006) (Hu et al., 2005) and 0.5 mg/ml of chemically synthesized Aβ42 (Sigma, A9810), total E. coli tRNA (0.6 mg/ml) (Sigma), total E. coli aminoacyl-tRNA synthetases (800 U/ml) (Sigma), 1 mM ATP, 30 mM KCl, 2 mM MgCl 2 , 2 mM β-mercaptoethanol, 2 μM L-arginine, 10 mM Tris-HCl (pH 8.0) and 0.1 μM [
14 C]L-arginine (PerkinElmer, NEN Radiochemicals, Waltham, MA). A reaction mixture (50 μl) was incubated for 30 min at 37°C, followed by the addition of the equal volume of 2xSDS sample buffer. Samples were then heated at 95°C for 10 min, followed by SDS-16.5% PAGE (Criterion Tris-Tricine gels; BioRad, #345-0063), electrophoretic transfer to 0.2 μm PVDF membranes using the iBlot apparatus (Invitrogen), and both autoradiography and immunoblotting, as described in the legend to Figure 4D .
